Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease.
Movement Disorders 31(7):1012 (2016)
Quantitative EEG features have been identified as surrogates and predictors of cognitive decline/dementia, a common feature of progressive PD. The biochemical correlates for altered quantitative EEG features are unknown. Our primary objective was to test the hypothesis that quantitative EEG meas...
Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study.
Journal of nuclear medicine : official publicat... 57(6):900 (2016)
Training for accurate image interpretation is essential for the clinical use of β-amyloid PET imaging, but the role of interpreter training and the accuracy of the algorithm for routine visual assessment of florbetaben PET scans are unclear. The aim of this study was to test the robustness of th...
Graph theory network function in Parkinson's disease assessed with electroencephalography.
Clinical Neurophysiology 127(5):2228 (2016)
To determine what differences exist in graph theory network measures derived from electroencephalography (EEG), between Parkinson's disease (PD) patients who are cognitively normal (PD-CN) and matched healthy controls; and between PD-CN and PD dementia (PD-D).
EEG recordings were analyzed via gr...
Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.
Neurology Neuroimmunology & Neuroinflammation 3(1):e193 (2016)
To identify a panel of peripheral inflammatory/immune mediators that could discriminate Parkinson disease with dementia (PDD) from Parkinson disease (PD) without dementia.
Plasma samples from 52 patients with PD and 22 patients with PDD were prepared from freshly collected blood following an ins...
Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders.
Journal of Parkinson's Disease 6(1):153 (2016)
Clinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy. Previously, we reported, from both autopsy and needle biopsy, a high prevalence of submandibular g...
Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases.
Journal of Neuropathology & Experimental Neurology 74(9):934 (2015)
The clinical diagnosis and classification of neurodegenerative diseases based on clinical examination or available biomarkers are currently insufficiently accurate. Although histologic examination is considered the gold standard for diagnosis, brain biopsies have been avoided because of the high...
REM sleep behavior disorder and neuropathology in Parkinson's disease.
Movement Disorders 30(10):1413 (2015)
Rapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson's disease (PD) is associated with differences in clinical phenotype, including dementia, autonomic loss, and gait dysfunction. The pathological basis for this remains unclear.
Parkinson's disease subjects in a longitudinal clini...
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.
Neuropathology 35(4):354 (2015)
The Brain and Body Donation Program (BBDP) at Banner Sun Health Research Institute (http://www.brainandbodydonationprogram.org) started in 1987 with brain-only donations and currently has banked more than 1600 brains. More than 430 whole-body donations have been received since this service was c...
Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.
Alzheimer's & Dementia 11(8):994 (2015)
Down syndrome (DS) is associated with amyloid b (Ab) deposition.
We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2),...
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Alzheimer's & Dementia 11(8):964 (2015)
Evaluation of brain β-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias.
Open-label, nonrandomized, multicenter, phase 3 study to validate the (18)F-labeled β-amyloid tracer florbetaben by comparing in vivo PET imaging...
Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.
Expert Opinion on Investigational Drugs 24(3):393 (2015)
Reduction in the deposition of amyloid β (Aβ) has been the primary target for Alzheimer's disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a target for trea...
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
JAMA Neurology 72(3):287 (2015)
In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease.
To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
Clinical characterization of mild cognitive impairment as a prodrome to dementia with Lewy bodies.
American Journal of Alzheimer's Disease and Oth... 30(2):173 (2015)
Limited information regarding the specificity of mild cognitive impairment (MCI) as it relates to dementia with Lewy bodies (DLB) exists. Here, we summarize the clinical phenotype of MCI in clinically suspect DLB. Ten patients with a primary diagnosis of MCI and secondary diagnoses of DLB were i...
Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.
Alzheimer's Research & Therapy 7(1):1 (2015)
Longitudinal assessment of cognitive decline in amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) often involves the use of both informant-based and objective cognitive assessments. As efforts have focused on identifying individuals in pre-clinical stages, instruments that a...
Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease.
Journal of Parkinson's Disease 5(1):117 (2015)
QEEG could provide physiological biomarkers for changes over time in Parkinson's disease (PD) cognitive decline if they track with longitudinal neuropsychological performance.
Our aim was to correlate longitudinal changes in frequency domain quantitative electroencephalography (QEEG) measures wi...
Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment.
BMC Neurology 15:146 (2015)
Although there are studies investigating the pathologic origins of mild cognitive impairment (MCI), they have revolved around comparisons to normal elderly individuals or those with Alzheimer's disease (AD) or other dementias. There are few studies directly comparing the comprehensive neuropatho...
Neuropsychological Correlates of the Alzheimer's Questionnaire.
Journal of Alzheimer's Disease 46(2):389 (2015)
Informant-based assessments of cognition and function are commonly used to differentiate individuals with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) from those who are cognitively normal. However, determining the extent to which informant-based measures correlate to o...
Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain.
Neurology and Therapy 3(2):79 (2014)
Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current clinical diagnostic tools are often ineffective in accurately diagnosing AD. However, new advances in diagnostic imaging, particularly positron emission tomography (PET) amyloid imaging, have show...
Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease.
Parkinsonism & Related Disorders 20(11):1260 (2014)
Olfactory dysfunction in Parkinson's disease (PD) is well-established and may represent one of the earliest signs of the disease.
The objective of this study was to evaluate the relationship of olfactory dysfunction, using the University of Pennsylvania Smell Identification Test (UPSIT), to clin...
Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease.
Neurobiology of Aging 35(9):1961 (2014)
Mild cognitive impairment (MCI) represents a cognitive state intermediate between normal aging and early Alzheimer's disease (AD). To investigate if the molecular signature of MCI parallels the clinical picture, we use microarrays to extensively profile gene expression in 4 cortical brain region...